Protocol Ledger

NCT07038200 · Phase III · RECRUITING

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

Interventional Phase III clinical trial protocol NCT07038200 sponsored by Avidity Biosciences in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-10 Enrollment: 200 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07038200
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)200 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07038200
Protocol FieldVerified Registry Value
NCT IdentifierNCT07038200
Consolidated Lead SponsorAvidity Biosciences
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment200 participants (ESTIMATED)
Registered Start Date2025-06-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI